Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Research

• Publication date

  2006-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-05-4563PMID 16818655
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histone deacetylation in epigenetics: An attractive target for anticancer therapy

  2005cited by this paper
• Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.

  2005cited by this paper
• TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.

  2005cited by this paper
• HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.

  2005cited by this paper
• Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death

  2005cited by this paper
• Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1

  2005cited by this paper
• Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

  2005cited by this paper
• Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.

  2005cited by this paper
• Histone deacetylase inhibitors: insights into mechanisms of lethality

  2005cited by this paper
• Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

  2005cited by this paper
• On the TRAIL of a new therapy for leukemia

  2005cited by this paper
• Activation of the Growth-Differentiation Factor 11 Gene by the Histone Deacetylase (HDAC) Inhibitor Trichostatin A and Repression by HDAC3

  2004cited by this paper
• Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells

  2004cited by this paper
• Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies

  2004cited by this paper
• Histone deacetylase inhibitors.

  2004cited by this paper
• The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

  2004cited by this paper
• Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.

  2004cited by this paper
• Histone deacetylases (HDACs): characterization of the classical HDAC family.

  2003influential reference
• Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.

  2003cited by this paper
• Death receptors leave a caspase footprint that Smacs of XIAP

  2003cited by this paper
• Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases

  2003influential reference
• Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases

  2003influential reference
• Fas-associated Death Domain Protein and Caspase-8 Are Not Recruited to the Tumor Necrosis Factor Receptor 1 Signaling Complex during Tumor Necrosis Factor-induced Apoptosis*

  2003cited by this paper
• Cell surface Death Receptor signaling in normal and cancer cells.

  2003cited by this paper
• Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)*

  2003cited by this paper
• The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

  2003cited by this paper
• Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.

  2003cited by this paper
• Role of class I and class II histone deacetylases in carcinoma cells using siRNA.

  2003cited by this paper
• FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.

  2002cited by this paper
• TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.

  2002cited by this paper
• Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.

  2002cited by this paper
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily

  2002cited by this paper
• Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia

  2002cited by this paper
• In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation

  2002influential reference
• HDAC6 is a microtubule-associated deacetylase

  2002influential reference
• Bcl-2 and Bcl-xL Inhibit CD95-mediated Apoptosis by Preventing Mitochondrial Release of Smac/DIABLO and Subsequent Inactivation of X-linked Inhibitor-of-Apoptosis Protein*

  2002cited by this paper
• Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

  2002cited by this paper
• Deacetylase enzymes: biological functions and the use of small-molecule inhibitors.

  2002cited by this paper
• TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

  2001cited by this paper
• Activity Synthetic Histone Deacetylase Inhibitor with Antitumor Cyclic Hydroxamic-acid-containing Peptide 31 , a Potent Updated Version

  2001cited by this paper
• Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

  2001cited by this paper
• The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

  2001cited by this paper
• Histone deacetylases and cancer: causes and therapies

  2001influential reference
• Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.

  2001cited by this paper
• TRAIL receptor-2 signals apoptosis through FADD and caspase-8

  2000cited by this paper
• A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library.

  2000cited by this paper
• FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2.

  2000cited by this paper
• Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.

  1999cited by this paper
• Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL*

  1997cited by this paper
• Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor.

  1995cited by this paper

• Leukemia Risk Factor ARID5B Coordinates HDAC-Mediated Transcriptional Repression

  2025cites this paper
• Histone Deacetylase Inhibitors Promote the Anticancer Activity of Cisplatin: Mechanisms and Potential

  2025cites this paper
• Design, synthesis, and evaluation of a novel TRAIL-activated HDAC6 inhibitor for the treatment of pulmonary fibrosis.

  2024cites this paper
• Chidamide triggers pyroptosis in T-cell lymphoblastic lymphoma/leukemia via the FOXO1/GSDME axis

  2024cites this paper
• Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression

  2023cites this paper
• Chemically Diverse S. mansoni HDAC8 Inhibitors Reduce Viability in Worm Larval and Adult Stages

  2022cites this paper
• Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates

  2022cites this paper
• Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer.

  2022cites this paper
• Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma

  2021cites this paper
• 8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1

  2021cites this paper
• Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy

  2019cites this paper
• An Overview of the Epigenetic Modifications of Gene Expression in Tumorigenesis

  2019cites this paper
• Histone Deacetylase Inhibitors in Cancer Therapy.

  2019cites this paper
• HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer

  2019cites this paper
• Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells

  2019cites this paper
• Small molecules as tools to study the chemical epigenetics of lysine acetylation.

  2018cites this paper
• Involvement of AMP-activated protein kinase and Death Receptor 5 in TRAIL-Berberine-induced apoptosis of cancer cells

  2018cites this paper
• Functions and epigenetic aspects of miR-15/16: Possible future cancer therapeutics

  2018cites this paper
• Epigenetic modifications in chronic myeloid leukemia cells through ruxolitinib treatment

  2018cites this paper
• Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma

  2017cites this paper
• Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression

  2017cites this paper
• Modulation of antitumor immunity with histone deacetylase inhibitors.

  2017cites this paper
• Understanding HDAC8-Catalyzed Deacetylation:From New Substrates to Diseases

  2017cites this paper
• Yakushinamides, Polyoxygenated Fatty Acid Amides That Inhibit HDACs and SIRTs, from the Marine Sponge Theonella swinhoei.

  2016cites this paper
• Metal-dependent Deacetylases: Cancer and Epigenetic Regulators.

  2016cites this paper
• Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors

  2016cites this paper
• MC1568 inhibits HDAC6/8 activity and influenza A virus replication in lung epithelial cells: role of Hsp90 acetylation.

  2016cites this paper
• Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma

  2016cites this paper
• Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.

  2015cites this paper
• Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6

  2015cites this paper
• Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage

  2015cites this paper
• Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.

  2015cites this paper
• Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.

  2015cites this paper
• Histone deacetylase inhibitors: potent anti-leukemic agents.

  2015cites this paper
• Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer

  2014cites this paper
• Syndromes myélodysplasiques et leucémies secondaires. Traitement

  2014cites this paper
• XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis

  2014cites this paper
• Lysine Deacetylase (KDAC) Regulatory Pathways: an Alternative Approach to Selective Modulation

  2014cites this paper
• A steered molecular dynamics mediated hit discovery for histone deacetylases.

  2014cites this paper
• HDAC as a therapeutic target for treatment of endometrial cancers.

  2014cites this paper
• Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I' mode

  2013cites this paper
• Inactivation of HDAC3 and STAT3 is Critically Involved in 1-Stearoyl-sn-Glycero-3-Phosphocholine-Induced Apoptosis in Chronic Myelogenous Leukemia K562 Cells

  2013cites this paper
• Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

  2013cites this paper
• Class II‐specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL‐8 expression in human melanoma cells

  2013cites this paper
• The Role of Histone Deacetylases in Cytokine Regulation in Human Gestational Tissues

  2013cites this paper
• Class I histone deacetylase inhibition modulates metalloproteinase expression and blocks cytokine-induced cartilage degradation.

  2013cites this paper
• Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.

  2013cites this paper
• tert‐Butylcarbamate‐Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells

  2013cites this paper
• Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells

  2013cites this paper
• Targeting apoptosis proteins in hematological malignancies.

  2013cites this paper
• Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6

  2013cites this paper
• Histone deacetylases and cancer

  2012cites this paper
• Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia.

  2012cites this paper
• Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity.

  2012cites this paper
• Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation

  2012cites this paper
• Expression of HDAC1 in leukemia cells

  2012cites this paper
• Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer

  2012cites this paper
• Acetylation of Histone Deacetylase 1 Regulates NuRD Corepressor Complex Activity*

  2012cites this paper
• Synthesis and Biological Evaluation of N-(Aminopyridine) Benzamide Analogues as Histone Deacetylase Inhibitors

  2012cites this paper
• Trends in the treatment of cutaneous T-cell lymphoma - critical evaluation and perspectives on vorinostat

  2012cites this paper
• Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4)

  2012cites this paper
• Histone Deacetylase in Chronic Lymphocytic Leukemia

  2012cites this paper
• A New Paradigm for an Old Story: The Role of Regulatory B Cells in Cancer

  2012cites this paper
• Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

  2012cites this paper
• Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis

  2011cites this paper
• Epigenomics of leukemia: from mechanisms to therapeutic applications.

  2011cites this paper
• Post-training intrahippocampal inhibition of class I histone deacetylases enhances long-term object-location memory.

  2011cites this paper
• The biology of HDAC in cancer: the nuclear and epigenetic components.

  2011cites this paper
• Molecular targets for selective killing of TRAIL-resistant leukemic cells

  2011cites this paper
• MicroRNAs in Predicting Radiotherapy and Chemotherapy Response

  2011cites this paper
• Synthesis and Biological Evaluation of Histone Deacetylase Inhibitor Largazole and Analogs

  2011cites this paper
• Entinostat for treatment of solid tumors and hematologic malignancies

  2011cites this paper
• Small-molecule chromatin-modifying agents: therapeutic applications.

  2010cites this paper
• Histone deacetylases and the immunological network: implications in cancer and inflammation

  2010cites this paper
• Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation

  2010cites this paper
• The role of histone deacetylases in cartilage gene regulation and chondroprotection

  2010cites this paper
• The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

  2010cites this paper
• Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands

  2010cites this paper
• Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells

  2010cites this paper
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy

  2010cites this paper
• Evaluation of Histone Deacetylases as Drug Targets in Huntington’s Disease models

  2010cites this paper
• HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.

  2010cites this paper
• LGP1, A histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis.

  2010cites this paper
• Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment.

  2010cites this paper
• Hydroxamic Acids: Biological Properties and Potential Uses as Therapeutic Agents

  2010cites this paper
• On the inhibition of histone deacetylase 8.

  2010cites this paper
• Role of histone deacetylases and their inhibitors in cancer biology and treatment.

  2010cites this paper
• Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma

  2009cites this paper
• Genetic dissection of histone deacetylase requirement in tumor cells

  2009cites this paper
• Histone post‐translational modifications by HPLC‐ESI‐MS after HT29 cell treatment with histone deacetylase inhibitors

  2009cites this paper
• HDAC family: What are the cancer relevant targets?

  2009cites this paper
• Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.

  2009cites this paper
• Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1

  2009cites this paper
• miR-449a targets HDAC-1 and induces growth arrest in prostate cancer

  2009cites this paper
• Cell death in hematological tumors

  2009cites this paper
• TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.

  2009cites this paper
• Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models.

  2009cites this paper
• Synergistic Induction of Apoptosis in Primary B-CLL Cells after Treatment with Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Histone Deacetylase Inhibitors

  2009cites this paper
• Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia

  2009cites this paper
• Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.

  2009cites this paper